MedTrace Logo

Lonafarnib With and Without Ritonavir in HDV (LOWR-1)

NCT02430181 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2022-11-29

Study results available
· View outcomes & findings →

Summary

To Evaluate the Safety and Efficacy of Lonafarnib with and without Ritonavir Boosting in Adults With Genotype 1 Chronic Hepatitis D Virus (HDV) Infection (LOWR-1).

Conditions

  • Chronic Hepatitis D Infection

Interventions

DRUG

lonafarnib

antiviral farnesyl transferase inhibitor

DRUG

peginterferon alfa-2a

immunomodulator

DRUG

ritonavir

CYP 3A4 inhibitor, lonafarnib booster

Sponsors & Collaborators

  • Eiger BioPharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Cihan Yurdaydin, MD · Ankara University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2015-09-30
Completion
2015-11-30
FDA Drug
Yes

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02430181 on ClinicalTrials.gov